European Investment Bank

Orano is a leading global company based in Courbevoie, France, specializing in nuclear power and renewable energy solutions. The company offers a comprehensive range of services covering every stage of the nuclear fuel cycle, including reactor design, construction, and operational support. With a strong emphasis on safety and advanced technology, Orano is committed to supplying low-carbon power generation solutions. Additionally, it engages in renewable energy initiatives through partnerships aimed at developing high-tech solutions. As energy demand increases and the need for sustainable practices intensifies, Orano focuses on creating cleaner energy alternatives that contribute to reducing greenhouse gas emissions. The company aims to enhance transparency, coherence, and efficiency in its operations while preparing for the future energy landscape.

Nomagic, Inc. is a technology company based in Warsaw, Poland, specializing in robotic manipulation solutions for order fulfillment in e-commerce. The company develops smart pick-and-place robotic systems that enhance efficiency, flexibility, and reliability in warehouses. By automating tedious tasks, Nomagic's solutions help reduce fulfillment costs and address labor shortages, allowing operations to scale effectively and operate around the clock. Powered by artificial intelligence, their robotic systems continuously learn and adapt to changing conditions, enabling warehouse operators to improve agility and ensure reliable delivery of goods. Nomagic's technology has been implemented in notable locations, including packing lines at Cdiscount, a leading French eCommerce platform.

Median Technologies SA is a company that specializes in developing and marketing software products for medical image analysis, primarily focused on oncology. Founded in 2002 and based in Valbonne, France, the company offers two main platforms: iBiopsy, which utilizes AI for biomarker identification and patient profiling through CT scans, and iSee, designed for image analysis and management in clinical trials. Median Technologies aims to enhance the diagnosis of cancer patients and assess their treatment responses by standardizing and automating medical image interpretation. The company operates in two main markets: drug development and patient care, and collaborates with a contract research organization to provide integrated imaging services for clinical trials. Additionally, it has partnered with Canon to innovate new imaging technologies for the patient care sector.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

Fab’entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂], targeting emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab’entech aims to provide healthcare institutions with effective treatments for urgent medical situations. As a member of the LyonBiopôle cluster, the company is positioned within a vibrant network dedicated to advancing biopharmaceutical innovation.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Endesa is an electric utility company headquartered in Madrid, Spain, that generates, distributes, and supplies electricity primarily in Spain and Portugal. Founded in 1944, the company has an installed generation capacity of 22 gigawatts, utilizing a diverse mix of energy sources, including hydroelectric, nuclear, coal, natural gas, oil, solar, and wind. Endesa serves approximately 11.2 million customers and employs over 10,000 people. In addition to its core electricity services, Endesa operates in the natural gas sector and provides energy-related services, emphasizing a commitment to sustainability and technological innovation to address current and future energy challenges. The company also supplies gas to retail and business customers in Spain and France.

SiPearl is a French semiconductor company established in 2019 and headquartered in Maisons-Laffitte, Île-de-France. The company specializes in designing high-performance, low-power microprocessors aimed at powering exascale supercomputers. Its flagship product, Rhea, is based on the Arm Neoverse V1 architecture and is set to be commercialized in early 2024. SiPearl's microprocessors are intended for a variety of applications, including computing, artificial intelligence, medical research, climate change mitigation, and energy management, catering to scientific researchers as well as prominent players in the IT, electronics, and automotive industries. The company is committed to producing its microprocessors using advanced manufacturing processes from TSMC, specifically N6 or better. SiPearl also maintains research and development centers across France, Germany, and Spain, aligning its roadmap with the European Union's technological goals.

Reden Solar is a company focused on the development, financing, construction, and operation of solar photovoltaic power plants across Europe and Latin America. With an installed portfolio of 762 megawatts and an additional 15 gigawatts under development, the company primarily operates in France and Spain while recently expanding into Greece and Italy. Reden Solar offers a diverse range of photovoltaic solutions, including agricultural greenhouses, ground-mounted plants, photovoltaic shelters, and rooftop installations. By providing these innovative energy solutions, Reden Solar aims to promote sustainable development and contribute to a cleaner planet through renewable energy production.

Orange is a global telecommunications company, founded in 1991 and headquartered in Paris, France. It operates in 30 countries across Europe and Africa, providing mobile and internet services to consumers, and corporate telecommunication services worldwide. Through its business arm, Orange Business Services, it caters to large corporates, local authorities, and SMEs, offering a comprehensive range of voice and data, IT, and integrated services. Additionally, Orange supports digital innovation through its international network of startup accelerators, Orange Fabs, which provides resources and expertise to startups in the digital space.

AB Science, established in 2001 by a team of researchers, clinicians, and entrepreneurs, is a France-based pharmaceutical company focused on developing innovative treatments for significant unmet medical needs. The company specializes in the research, discovery, development, and marketing of protein kinase inhibitors, particularly tyrosine kinase inhibitors. These targeted therapies aim to treat various diseases, including cancer, chronic inflammatory diseases, neurological degenerative disorders, and central nervous system diseases, with applications in both human and veterinary medicine.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

AB Science, established in 2001 by a team of researchers, clinicians, and entrepreneurs, is a France-based pharmaceutical company focused on developing innovative treatments for significant unmet medical needs. The company specializes in the research, discovery, development, and marketing of protein kinase inhibitors, particularly tyrosine kinase inhibitors. These targeted therapies aim to treat various diseases, including cancer, chronic inflammatory diseases, neurological degenerative disorders, and central nervous system diseases, with applications in both human and veterinary medicine.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.

OVH APAC is a leading cloud provider known for its innovative and cost-effective solutions tailored for a diverse clientele, ranging from startups to large enterprises. Founded in 1999 by Octave Klaba and based in France, OVH offers a comprehensive portfolio of services, including web hosting, dedicated servers, cloud solutions, domain registration, and VOIP telephony. The company distinguishes itself through its proprietary global fiber-optic network and green data centers, which enable optimal performance and reliability. With a commitment to research and development and complete control over its supply chain, OVH delivers high-quality products and exceptional customer service. Additionally, OVH has established a strong partnership with VMware, integrating advanced software solutions to enhance network performance and streamline service delivery for its customers. As a result, OVH is recognized as one of the top internet hosting companies globally, serving millions of customers with cutting-edge technology and expertise.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Prophesee SA, founded in 2014 and based in Paris, France, specializes in developing advanced machine vision sensors and systems. Renowned for its neuromorphic vision technology, the company has created a unique visual processing platform that mimics human vision by detecting events rather than capturing sequences of images. This innovative Metavision® approach enables significant advancements in speed, dynamic range, data efficiency, and power consumption, making it suitable for a variety of applications including autonomous driving, mobile devices, industrial automation, and security systems. Prophesee serves a diverse clientele across multiple sectors such as biomedical, gaming, robotics, and aerospace. The company boasts a team of over 100 engineers and holds more than 50 international patents, positioning itself as a leader in next-generation vision technologies.

Nomagic, Inc. is a technology company based in Warsaw, Poland, specializing in robotic manipulation solutions for order fulfillment in e-commerce. The company develops smart pick-and-place robotic systems that enhance efficiency, flexibility, and reliability in warehouses. By automating tedious tasks, Nomagic's solutions help reduce fulfillment costs and address labor shortages, allowing operations to scale effectively and operate around the clock. Powered by artificial intelligence, their robotic systems continuously learn and adapt to changing conditions, enabling warehouse operators to improve agility and ensure reliable delivery of goods. Nomagic's technology has been implemented in notable locations, including packing lines at Cdiscount, a leading French eCommerce platform.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Kayrros is a prominent advanced data analytics company specializing in the energy sector, aiding global market participants in making informed investment decisions. With a team of over 100 professionals from more than 15 nationalities, the company operates from its headquarters in Paris and additional offices in Houston, London, New York, and Singapore. Kayrros integrates alternative and market data into unique product offerings that provide actionable insights in near real-time, utilizing advanced technologies. The company's platform focuses on environmental intelligence and asset observation, delivering critical insights on energy-transition risks and climate impacts. This enables decision-makers in various sectors, including government and investment markets, to evaluate the effects of energy and industrial activities on the environment, thereby facilitating better and faster decision-making. Kayrros continuously expands its solutions to enhance transparency in the global energy markets.

Priothera Ltd is a clinical-stage biotechnology company based in Dublin, Ireland, with an additional location in Saint Louis, France. Founded in 2020, Priothera specializes in the development of orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's leading candidate, mocravimod, is designed to reduce the egress of T cell subsets from lymphatic tissue, thereby enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. By providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects, Priothera aims to significantly improve outcomes for patients undergoing such transplants.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Bouygues Telecom is a prominent telecommunications operator in France, offering a wide range of services that include mobile, fixed-line, television, internet, and cloud computing. The company serves approximately 11.1 million mobile customers and 2.1 million fixed broadband customers, including over 1.5 million professional and corporate clients. Renowned for its innovative approach, Bouygues Telecom has introduced several pioneering products, such as the first unlimited call plans, fixed-mobile convergence offers for corporate customers, and the quadruple play solution known as ideo. The company also launched B&YOU, a web-only offer that revolutionized mobile telephony. With a mobile network that covers 99% of the population and a rapidly expanding 4G network, Bouygues Telecom is committed to enhancing customer experience through its dedicated team of over 9,000 employees and a robust customer service framework that includes 2,000 advisers and 2,500 sales staff. The company's focus on innovation and customer satisfaction positions it as a key player in the French telecommunications market.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.

Median Technologies SA is a company that specializes in developing and marketing software products for medical image analysis, primarily focused on oncology. Founded in 2002 and based in Valbonne, France, the company offers two main platforms: iBiopsy, which utilizes AI for biomarker identification and patient profiling through CT scans, and iSee, designed for image analysis and management in clinical trials. Median Technologies aims to enhance the diagnosis of cancer patients and assess their treatment responses by standardizing and automating medical image interpretation. The company operates in two main markets: drug development and patient care, and collaborates with a contract research organization to provide integrated imaging services for clinical trials. Additionally, it has partnered with Canon to innovate new imaging technologies for the patient care sector.

Orange is a global telecommunications company, founded in 1991 and headquartered in Paris, France. It operates in 30 countries across Europe and Africa, providing mobile and internet services to consumers, and corporate telecommunication services worldwide. Through its business arm, Orange Business Services, it caters to large corporates, local authorities, and SMEs, offering a comprehensive range of voice and data, IT, and integrated services. Additionally, Orange supports digital innovation through its international network of startup accelerators, Orange Fabs, which provides resources and expertise to startups in the digital space.

Prophesee SA, founded in 2014 and based in Paris, France, specializes in developing advanced machine vision sensors and systems. Renowned for its neuromorphic vision technology, the company has created a unique visual processing platform that mimics human vision by detecting events rather than capturing sequences of images. This innovative Metavision® approach enables significant advancements in speed, dynamic range, data efficiency, and power consumption, making it suitable for a variety of applications including autonomous driving, mobile devices, industrial automation, and security systems. Prophesee serves a diverse clientele across multiple sectors such as biomedical, gaming, robotics, and aerospace. The company boasts a team of over 100 engineers and holds more than 50 international patents, positioning itself as a leader in next-generation vision technologies.

FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.

Mobidiag is a Finnish-French biotechnology company specializing in the development and marketing of molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. The company utilizes established technologies such as real-time polymerase chain reaction (qPCR) and microarray to create a wide array of diagnostic tests and automated platforms. These solutions are designed to be fast, reliable, and cost-effective, catering to laboratories of various sizes. Mobidiag's offerings enable the detection of a majority of clinically relevant pathogens, including bacteria, parasites, and viruses, as well as important markers for antibiotic resistance, thereby enhancing diagnostic capabilities in hospitals, laboratories, and clinics.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

MotorK is a software as a service (SaaS) provider focused on the automotive retail industry in the EMEA region, employing over 400 staff across eleven offices in eight countries, including Italy, Spain, France, Germany, Portugal, the UK, Belgium, and Israel. The company specializes in developing digital sales and marketing solutions that enhance customer experience for car manufacturers and dealers. MotorK offers a comprehensive suite of integrated digital products and services, including platforms for traffic acquisition, inventory management, sales operations, and promotional campaigns. Key products include WebSparK, a web module known for its technical and design excellence, and StockSparK, a stock management tool that aggregates and enhances inventory visibility for potential buyers. With a strong emphasis on innovation, MotorK boasts one of the largest research and development teams in the European automotive digital sales and marketing sector.

Mobidiag is a Finnish-French biotechnology company specializing in the development and marketing of molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. The company utilizes established technologies such as real-time polymerase chain reaction (qPCR) and microarray to create a wide array of diagnostic tests and automated platforms. These solutions are designed to be fast, reliable, and cost-effective, catering to laboratories of various sizes. Mobidiag's offerings enable the detection of a majority of clinically relevant pathogens, including bacteria, parasites, and viruses, as well as important markers for antibiotic resistance, thereby enhancing diagnostic capabilities in hospitals, laboratories, and clinics.

Navya SA is a prominent French company specializing in autonomous vehicle technology and smart shared mobility solutions. Founded in 2014 and headquartered in Villeurbanne, France, Navya develops, manufactures, and services a range of driverless electric vehicles, including autonomous shuttles and cabs. The company primarily caters to municipalities, industrial sites, universities, theme parks, and airports, and its products are available in the United States, EMEA, and Asia-Pacific regions. Navya has been a pioneer in the autonomous mobility sector, launching its first shuttle, the AUTONOM®SHUTTLE, in 2015, with over 100 units produced and sold in multiple countries. The AUTONOM®CAB, introduced in 2017, is set to undergo road tests soon. With a workforce of more than 200 employees in France and the United States, Navya combines advanced robotic and digital technologies to deliver innovative mobility solutions.

October is a pan-European lending platform that aims to empower businesses by simplifying access to funding. Founded in France in 2014 under the name Lendix, the company emerged following regulatory changes that disrupted traditional banking practices. With offices in France, Spain, Italy, and the Netherlands, October operates an online marketplace that connects private investors with enterprises of various sizes. This platform allows investors to finance businesses directly, offering fully disclosed terms and facilitating a streamlined investment process. Institutional lenders complement individual contributions, ensuring borrowers benefit from high success rates and quick processing times. October's mission is to democratize finance, providing a secure and efficient way for individuals to invest in the real economy.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Forsee Power SAS, founded in 2007 and based in Ivry-sur-Seine, France, specializes in the design and manufacture of smart lithium-ion battery systems. The company serves various sectors, including electric transportation, portable and mobile equipment, and energy storage. Its product offerings include modular battery systems for electric and hybrid vehicles, trams, electric trains, buses, trucks, and marine applications such as ships and ferries. Additionally, Forsee Power provides power systems for mobile and connected devices across numerous fields, including medical equipment, electric scooters, and robotics. The company's focus on innovation and customer satisfaction aims to facilitate a sustainable energy transition and enhance the performance of smart mobility and life devices globally.

SunPartner Technologies, founded in 2008 and based in Rousset, France, specializes in the development and commercialization of advanced photovoltaic technologies. The company focuses on integrating solar solutions into various applications, including mobile devices and infrastructure. Its notable products include Wysips Crystal, an ultra-thin and transparent photovoltaic material designed for smartphones and smartwatches, and Wysips Graphics, which incorporates solar cells into connected devices. Additionally, SunPartner offers Wysips Reflect for reflective screens and Wysips Cameleon for signage and billboards. The company also explores innovations in communication technologies, such as Light-Fidelity, which utilizes visible light for data transmission, applicable in smart cities and location-based services. Through its diverse portfolio, SunPartner aims to enhance energy autonomy and promote sustainable energy solutions in multiple sectors.

Electro Power Systems operates in the sustainable energy sector, focusing on hybrid-storage solutions and microgrids that convert intermittent renewable energy into a reliable power source. Headquartered in Paris, with research, development, and manufacturing facilities in Italy, the company has developed innovative hybrid energy storage technologies, supported by 125 patents and over a decade of research and development. These solutions are designed to stabilize electrical grids with high levels of renewable energy integration in developed countries and provide cost-effective off-grid power in emerging economies without relying on subsidies. Electro Power Systems has successfully implemented and is commissioning 36 large-scale projects, including off-grid hybrid systems and grid support systems, totaling over 47 MWh of capacity across 21 countries, serving more than 165,000 customers daily.

Mobidiag is a Finnish-French biotechnology company specializing in the development and marketing of molecular diagnostic solutions aimed at detecting gastrointestinal infections, antimicrobial resistance, healthcare-associated infections, respiratory infections, and sepsis. The company utilizes established technologies such as real-time polymerase chain reaction (qPCR) and microarray to create a wide array of diagnostic tests and automated platforms. These solutions are designed to be fast, reliable, and cost-effective, catering to laboratories of various sizes. Mobidiag's offerings enable the detection of a majority of clinically relevant pathogens, including bacteria, parasites, and viruses, as well as important markers for antibiotic resistance, thereby enhancing diagnostic capabilities in hospitals, laboratories, and clinics.

Bordeaux Métropole Énergies (BME) is a semi-public energy group headquartered in Bordeaux, France, and is 76% controlled by Bordeaux Métropole. BME is an important actor in the local energy transformation, servicing the Gironde region and the surrounding Bordeaux metropolitan area.